전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Research article


References

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270-273.
  2. Cucinotta D, Vanelli M. 2020. WHO Declares COVID-19 a Pandemic. Acta Biomed. 91: 157-160.
  3. Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. 2020. The socio-economic Implications of the Coronavirus and COVID-19 Pandemic: a review. Int. J. Surg. 78: 185-193.
  4. Lake MA. 2020. What we know so far: COVID-19 current clinical knowledge and research. Clin. Med. (Lond) 20: 124-127.
  5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. 2020. Clinical characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 382: 1708-1720.
  6. Weiss P, Murdoch DR. 2020. Clinical course and mortality risk of severe COVID-19. Lancet 395: 1014-1015.
  7. Lee JY, Bae S, Myoung J. 2019. Middle east respiratory syndrome Coronavirus-encoded accessory proteins Impair MDA5-and TBK1-Mediated Activation of NF-kappaB. J. Microbiol. Biotechnol. 29: 1316-1323.
  8. Lee JY, Kim SJ, Myoung J. 2019. Middle east respiratory syndrome Coronavirus-encoded ORF8b inhibits RIG-I-Like receptors in a differential mechanism. J. Microbiol. Biotechnol. 29: 2014-2021.
  9. Lee J, Bae S, Myoung J. 2019. Generation of full-length infectious cDNA clones of middle east respiratory syndrome Coronavirus. J. Microbiol. Biotechnol. 29: 999-1007.
  10. Ashburn TT, Thor KB. 2004. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3: 673-683.
  11. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. 2020. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 382: 1787-1799.
  12. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. 2020. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 382: 2327-2336.
  13. Kim HS, Lee K, Kim SJ, Cho S, Shin HJ, Kim C, et al. 2018. Arrayed CRISPR screen with image-based assay reliably uncovers host genes required for coxsackievirus infection. Genome Res. 28: 859-868.
  14. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30: 269-271.
  15. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 80: 5059-5064.
  16. Amery WK. 1983. Flunarizine, a calcium channel blocker: a new prophylactic drug in migraine. Headache 23: 70-74.
  17. Ishii M, Kobayashi S, Ohkura M, Yamamoto R, Shimizu S, Kiuchi Y. 2009. Inhibitory effect of lomerizine, a prophylactic drug for migraines, on serotonin-induced contraction of the basilar artery. J. Pharmacol. Sci. 111: 221-225.
  18. Wang S, Liu Y, Guo J, Wang P, Zhang L, Xiao G, et al. 2017. Screening of FDA-Approved drugs for Inhibitors of Japanese Encephalitis Virus infection. J. Virol. 91: e01055-17.
  19. Perin PM, Haid S, Brown RJ, Doerrbecker J, Schulze K, Zeilinger C, et al. 2016. Flunarizine prevents hepatitis C virus membrane fusion in a genotype-dependent manner by targeting the potential fusion peptide within E1. Hepatology 63: 49-62.
  20. Johansen LM, DeWald LE, Shoemaker CJ, Hoffstrom BG, Lear-Rooney CM, Stossel A, et al. 2015. A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. Sci. Transl. Med. 7: 290ra289.
  21. Nathan L, Lai AL, Millet JK, Straus MR, Freed JH, Whittaker GR, et al. 2020. Calcium ions directly interact with the Ebola virus fusion peptide to promote structure-function changes that enhance infection. ACS Infect. Dis. 6: 250-260.
  22. Wibble T, Engstrom J, Verrecchia L, Pansell T. 2020. The effects of meclizine on motion sickness revisited. Br. J. Clin. Pharmacol. 86: 1510-1518.
  23. Guo J, Li W, Wu Y, Jing X, Huang J, Zhang J, et al. 2017. Meclizine prevents ovariectomy-induced bone loss and inhibits osteoclastogenesis partially by upregulating PXR. Front. Pharmacol. 8: 693.
  24. Mostafa GA, Al-Badr AA. 2011. Buclizine. Profiles Drug Subst. Excip. Relat. Methodol. 36: 1-33.
  25. D’Alessandro S, Scaccabarozzi D, Signorini L, Perego F, Ilboudo DP, Ferrante P, et al. 2020. The use of antimalarial drugs against viral infection. Microorganisms. 8: 85.
  26. Han Y, Mesplede T, Xu H, Quan Y, Wainberg MA. 2018. The antimalarial drug amodiaquine possesses anti-ZIKA virus activities. J. Med. Virol. 90: 796-802.
  27. Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. 2014. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 58: 4885-4893.
  28. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45: 883-893.
  29. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362: 1142-1151.
  30. Kim C, Kang H, Kim DE, Song JH, Choi M, Kang M, et al. 2016. Antiviral activity of micafungin against enterovirus 71. Virol. J. 13: 99.
  31. Ho YJ, Liu FC, Yeh CT, Yang CM, Lin CC, Lin TY, et al. 2018. Micafungin is a novel anti-viral agent of chikungunya virus through multiple mechanisms. Antiviral. Res. 159: 134-142.
  32. Ansarin K, Tolouian R, Ardalan M, Taghizadieh A, Varshochi M, Teimouri S, et al. 2020. Effect of bromhexine on clinical outcomes and mortality in COVID-19 patients: A randomized clinical trial. Bioimpacts 10: 209-215.
  33. Antoszczak M, Maj E, Napiorkowska A, Stefanska J, Augustynowicz-Kopec E, Wietrzyk J, et al. 2014. Synthesis, anticancer and antibacterial activity of salinomycin N-benzyl amides. Molecules 19: 19435-19459.
  34. Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, et al. 2020. Potential antiviral options against SARS-CoV-2 infection. Viruses 12: 642.
  35. Vogel JU, Schmidt S, Schmidt D, Rothweiler F, Koch B, Baer P, et al. 2019. The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation. Cells 9: 31.

Related articles in JMB

More Related Articles